Related Experiment Videos
Amicarbalide: a therapeutic agent for anaplasmosis
The Onderstepoort Journal of Veterinary Research
|September 1, 1978
Summary
Amicarbalide effectively controlled acute Anaplasma infections in cattle at 20 mg/kg. However, it failed to eliminate latent infections and showed significant liver and kidney toxicity at higher doses.
Area of Science:
- Veterinary Medicine
- Parasitology
- Toxicology
Background:
- Anaplasmosis, caused by Anaplasma species, is a significant tick-borne disease affecting cattle.
- Effective treatments for acute and latent Anaplasma infections are crucial for livestock health and productivity.
Purpose of the Study:
- To evaluate the efficacy of amicarbalide in controlling acute and latent Anaplasma marginale and Anaplasma centrale infections in cattle.
- To assess the toxicological profile of amicarbalide at different dosage rates.
Main Methods:
- Cattle, both intact and splenectomized, were treated with amicarbalide subcutaneously.
- Different dosage rates were administered to assess efficacy and toxicity.
- Infections were monitored for acute and latent Anaplasma presence.
Main Results:
- Amicarbalide at 20 mg/kg effectively controlled acute Anaplasma marginale and Anaplasma centrale infections.
- Treatment failed to eliminate patent and latent Anaplasma infections.
- Doses of 40 mg/kg and above demonstrated significant hepato- and nephrotoxic effects.
Conclusions:
- Amicarbalide shows promise for managing acute Anaplasma infections in cattle.
- Its inability to clear latent infections and its dose-dependent toxicity limit its therapeutic application.
- Further research into safer and more comprehensive Anaplasma treatments is warranted.